Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Elekta AB ( ($SE:EKTA.B) ).
Elekta has received U.S. FDA 510(k) clearance for its Gamma Knife radiosurgery system to treat refractory, drug-resistant mesial temporal lobe epilepsy (MTLE) in adults. This clearance allows U.S. providers to offer a non-invasive, precision treatment option for epilepsy, potentially improving patient outcomes and optimizing resource utilization. The Gamma Knife system, originally developed for functional indications like epilepsy, has been a non-invasive alternative for nearly two million patients globally, sparing healthy brain tissue and critical structures.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta is a leader in precision radiation therapy, dedicated to providing the best cancer care possible. The company collaborates with customers to develop sustainable, outcome-driven, and cost-efficient solutions to meet patient needs. Headquartered in Stockholm, Sweden, Elekta operates in over 40 countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 1,288,171
Technical Sentiment Signal: Sell
Current Market Cap: SEK18.13B
For an in-depth examination of EKTA.B stock, go to TipRanks’ Overview page.